Navigation Links
Thoratec Announces Appointment of Steven H. Collis to Board of Directors
Date:11/19/2007

PLEASANTON, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in products to treat cardiovascular disease, today announced the appointment of healthcare executive Steven H. Collis to its board of directors, effective January 1, 2008. His appointment brings the Thoratec board to nine directors.

Collis, who will join the board's compensation and option committee, is executive vice president of AmerisourceBergen Corporation, and president of its Dallas-based AmerisourceBergen Specialty Group (ABSG). ABSG delivers specialty pharmaceuticals and related services to physician offices, including reimbursement consulting and physician education.

Collis joined AmerisourceBergen in 1994 as a general manager in ASD Specialty Healthcare, and was named president of its Specialty Group in 1999. He was previously a principal and general manager of Sterling Medical, a national provider and distributor of medical disposable supplies, health management services and continuous quality management programs to the home care market.

Born and educated in South Africa, Collis holds a Bachelor of Commerce with Honors degree from the University of the Witwatersrand in Johannesburg. He received his Charter Accountancy license, the South African equivalent of a Certified Public Accountant license.

"We are very excited to have someone with Steve's extensive and impressive operational expertise join our board. Steve's experience shepherding ABSG through extensive growth provides him with insight that will be of great value to Thoratec," said Gary F. Burbach, president and chief executive officer of Thoratec. "We are certain Steve will make a meaningful contribution to the board and
'/>"/>

SOURCE Thoratec Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. Thoratec Presentation at Bear Stearns Conference To Be Webcast
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2008)...e-FirstCall/ -- PURE Bioscience (Nasdaq:,PURE), cr...rogen citrate,(SDC), today reported revenues for t...which increased more than 340% compared with $336,... a loss from operations before taxes,of $(6,540,30...$(4,654,900), or $(0.19) per share, in the prior y...
(Date:10/15/2008)...FirstCall/ - GeneNews Limited (TSX: GEN),a compan...s for the early,detection of diseases and personal...s appointed Patrick Terry as its lead strategic ad...y(TM), the world,s fist blood-based,test to determ... Mr. Terry,is one of the co-founders of Genomic He...
(Date:10/14/2008)...gma-Aldrich,s leading MISSION(TM) shRNA ... /- Sigma-Aldrich (Nasdaq: SIAL ), a...Ai Consortium (TRC),proudly welcomes the Memorial...ship Program ( http://sigma-aldrich.com/rpp ). The...h access to cutting-edge products in,Sigma-Aldrich...
(Date:10/14/2008)...ss Results to Be Held at 9:00 A.M. -, EXTON, Pa.,...rporated,s,(Nasdaq: VPHM ) third quarter financia...Wednesday, October 29, 2008 before the open of the... conference call and live audio webcast at 9:00,a....ence call, ViroPharma,management will discuss the ...
Breaking Biology Technology:PURE Bioscience Reports Fourth Quarter and Year End Results 2PURE Bioscience Reports Fourth Quarter and Year End Results 3PURE Bioscience Reports Fourth Quarter and Year End Results 4PURE Bioscience Reports Fourth Quarter and Year End Results 5PURE Bioscience Reports Fourth Quarter and Year End Results 6PURE Bioscience Reports Fourth Quarter and Year End Results 7GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM) 2Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program 2Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program 3ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008 2
... Technology Network (WTN) just turned one! It is b...ee what we have accomplished in just 12 months of ...by Amazon and powered by Goggle) wistechnology.co... reach, and page views compared to other technolog...st. WTN is read beyond Wisconsin with 30% of its, ...
...over Spirit, which bounced to a near pinpoint land...Saturday (Jan. 3) after a seven-month flight, prom...Madison scientists say. , ,John Valley, a UW-Madis...ducted isotopic analyses of meteorites believed to...onsiderably to our knowledge of Mars and whether o...
...,Lets start with the good in Midwest biotech in 20...ormance of the publicly traded Midwest biotech com... Index, which evaluates the top 20 biotech stocks ...tellar performance of the Nasdaq and Amex Biotech ...lly ticked up even more in the last trading days o...
.... - GE Medical Systems and University Community H...ealth network based in Tampa, Florida have announc...dvanced heart hospitals. GE Medical Systems will...scular hospital, designed to deliver cardiovascula...hnology, when it opens in the spring of 2005. , ,...
Other Biology Technology:WTN's First Year 2The Good, Bad, Ugly of Midwest Biotech in 2003 2The Good, Bad, Ugly of Midwest Biotech in 2003 3GE Medical Enables Digital Heart Hospital 2GE Medical Enables Digital Heart Hospital 3
(Date:10/14/2008)...es for finding life on other planets and in extrem...State,s new astrobiology initiative under a five-y...Signatures of Life from Earth and Beyond." , Chr...ces, will lead an interdisciplinary team to develo...r biological signatures in relevant ecosystems in ...
(Date:10/14/2008)...e is available in Spanish . , An interdiscipli...at the Institute for Research in Biomedicine (IRB ...Catal d,Investigaci Qumica" (ICIQ, Tarragona), hav...tain protein p53 stable even when it presents cert...r. Giralt, head of the Chemistry and Molecular Pha...
(Date:10/14/2008)... 14, 2008Three years after Hurricane Katrina devas...ses of the destruction of the city,s floodwall sys...Entomologist (Vol. 54, No. 3) suggests that Formo... Author Gregg Henderson, a professor at the Louisi... subterranean termites (Coptotermes formosanus Shi...
(Date:10/14/2008)...r Health and Nutrition announced the publication o...en associated with the health benefits of red wine...ts. In the September 24 edition of the Journal o...ort that cocoa powder, baking chocolate and dark c...l, a naturally occurring antioxidant. , "This s...
Breaking Biology News(10 mins):Penn State receives new NASA astrobiology grant 2Penn State receives new NASA astrobiology grant 3Design of a compound that stabilizes the main natural suppressor of tumors 2Did termites help Katrina destroy New Orleans floodwalls? 2Resveratrol, red wine compound linked to health, also found in dark chocolate and cocoa 2HealthSouth Issues Statement on Medicare Bill and 75 25 Rule 8625 1HealthSouth Issues Statement on Medicare Bill and 75 25 Rule 8625 2Kiwa Signs Letter of Intent with Huaxing Animal Medicine 2338 1Kiwa Signs Letter of Intent with Huaxing Animal Medicine 2338 2Kiwa Signs Letter of Intent with Huaxing Animal Medicine 2338 3ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease 2335 1ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease 2335 2ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease 2335 3ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease 2335 4Human embryonic stem cell lines created that avoid immune rejection 8621 1Human embryonic stem cell lines created that avoid immune rejection 8621 2
...r all its promise, the prospect of using nanoparti...cts has raised concerns about possible harmful eff... University of Michigan are addressing those conce...icles damage cell membranes---enough to cause cell...revented. , "If you,re inventing these sorts of ma...
...ees in the world¹s most productive forests -- fore... tend to die young, according to a U.S. Geological...f the journal Ecology Letters. This discovery coul... to ongoing and future environmental changes. , "O...the world¹s most productive forests may be those l...
...ltiple sclerosis (MS) can be an unpredictable dise...acks healthy nerve cells and disrupts normal nerve...mptoms—including tingling, paralysis, pain, fatigu...y or in combination, sporadically or persistently....flare-ups are common in the majority of patients. ...
...number of articles explore the use of positron emi...onsurgical techniques that open the door to unders...issue of the Society of Nuclear Medicine,s Journal...nimal imaging "is the ability to carry out many st..." said SNM member Michael J. Welch, Ph.D., co-auth...
Other Biology News:Probing the promise and perils of nanoparticles 2Live fast, die young true for forests too 2Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients 2Use of PET can reduce, may eliminate more strenuous drug development trials with animals 2Use of PET can reduce, may eliminate more strenuous drug development trials with animals 3Use of PET can reduce, may eliminate more strenuous drug development trials with animals 4
Rad51B
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies.
Biology Products: